ERBB2 and breast cancer: Among all the breast cancer, hormone receptor-positive breast cancer constitutes approximately 60%–70% (Hart et al., 2015), while the proportion of triple negative breast cancer (TNBC) is about 15%–20% (Marra et al., 2019), and the remainder are HER2-positive breast cancer subtype.